477600-74-1 Usage
Description
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a chemical compound that serves as an intermediate in the synthesis of (3S,4R)-Tofacitinib (T528010), an enantiopure stereoisomer of the drug Janus kinase 3 (Jak3) inhibitor (CP-690,550). N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine plays a crucial role in the development of pharmaceuticals targeting specific kinases, which are essential in various cellular processes.
Uses
Used in Pharmaceutical Industry:
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is used as an intermediate in the synthesis of (3S,4R)-Tofacitinib (T528010) for its role as a Janus kinase 3 (Jak3) inhibitor. The application reason is that it helps in the development of drugs that can inhibit selected members of the STE7 and STE20 subfamily of kinases, which are involved in various cellular processes and are potential therapeutic targets for various diseases.
Used in Research and Development:
In the field of research and development, N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is used as a key compound in the synthesis of novel Jak3 inhibitors. The application reason is to explore the potential of these inhibitors in treating various diseases by targeting the specific kinases involved in their pathogenesis.
Used in Drug Design and Optimization:
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is also used in drug design and optimization processes. The application reason is to improve the potency, selectivity, and pharmacokinetic properties of Jak3 inhibitors, leading to more effective and safer therapeutic options for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 477600-74-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,7,6,0 and 0 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 477600-74:
(8*4)+(7*7)+(6*7)+(5*6)+(4*0)+(3*0)+(2*7)+(1*4)=171
171 % 10 = 1
So 477600-74-1 is a valid CAS Registry Number.
InChI:InChI=1/C13H19N5/c1-9-3-5-14-7-11(9)18(2)13-10-4-6-15-12(10)16-8-17-13/h4,6,8-9,11,14H,3,5,7H2,1-2H3,(H,15,16,17)/t9-,11+/m1/s1
477600-74-1Relevant articles and documents
Preparation method of tofacitinib citrate
-
, (2021/04/21)
The invention discloses a preparation method of tofacitinib citrate. The method comprises the following steps: by taking 7-tert-butyloxycarbonyl-4-amino-7H-pyrrolo[2, 3-D]pyrimidine and 1-benzyl-4-methyl-piperidine-3-ketone as initial raw materials, carrying out condensation under a weak acidic condition, then carrying out N methylation, selective reduction, debenzylation and Boc removal, and carrying out ester exchange and citric acid salification at a high temperature to obtain the tofacitinib citrate. The method has the advantages of mild reaction conditions, simple post-treatment mode, reduction of the generation amount of hazardous wastes, environmental protection, cost saving, and facilitation of industrial production.
Short enantioselective total synthesis of (+)-tofacitinib
Mane, Kishor D.,Kamble, Rohit B.,Suryavanshi, Gurunath
, (2021/02/20)
An enantioselective total synthesis of Tofacitinib (CP-690,550), a Janus tyrosine kinase (JAK3) specific inhibitor has been achieved from the readily available 4-piperidone. Proline catalysed hydroxylation is the key step for the synthesis of enantiopure 1-benzyl-4-methylpiperidin-3-ol.
Synthesis method of tofacitinib citrate
-
, (2021/12/07)
The invention discloses a tofacitinib citrate synthesis method, belongs to the technical field of tofacitinib citrate preparation, and can effectively inhibit activity of Janus and JAK1 JAK3, block signal transduction of various inflammatory cytokines, and has an expensive catalyst application in the existing synthesis step. The method uses 1 - benzyl -4 - methyl -3 - (methylamino) piperidine hydrochloride as a raw material to prepare the tofacitinib citrate as a raw material, and then the citric acid tofacitinib citrate is obtained through twice refining 4 -7 - and the - 7H - yield and 2 the 3 - D purity of the tofacitinib citrate are improved.